

REMARKS

In the Office Action, the Examiner subjected the claims to a restriction requirement under 35 U.S.C. §121, in which restriction has been required between the following groups of claims (in which claims 56-66 were re-numbered to be claims 55-65):

Group I	claims 1-15 (isolated nucleic acid molecules, vectors, host cells).
Group II	claims 16-22, 49-54 (GFR α 3 polypeptides and chimeric polypeptides)
Group III	claims 23-24, (antibodies to a GFR α 3 polypeptide)
Group IV	claim 25 (method of treating a neuronal disorder with a GFR α 3 antibody)
Group V	claims 26-29 (method of measuring agonist binding to GFR α 3 receptor)
Group VI	claims 30-48, 55-65 (methods of measuring GFR α 3 autophosphorylation, kits)


Applicants hereby elect with traverse Group 3 (Claims 23-24) drawn to antibodies to a GFR α 3 polypeptide.

The grounds for traversal of this Restriction Requirement include the grounds that the nucleic acids, vectors, host cells, polypeptides, antibodies, and kits are all related by the polypeptides encoded by the nucleic acids, that is, they are all related by the gene products common to all groups. The methods are also related for the same or similar reasons, in that these methods relate to the common genes and gene products, to the effects of agents on such gene products, and to the actions of such gene products.

Although no fees are believed to be due, please charge any fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. **08-1641 (39766-0065 DV1)**.

Respectfully submitted,

Date: January 12, 2006

By: 
James A. Fox (Reg. No. 38,455)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Direct Dial: (650) 324-6951
Telephone: (650) 324-7000
Facsimile: (650) 324-6654

SV 2178947 v1